Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ
$240.69
▲ UP 1.51% (3.59)

KEY STATISTICS

Market Cap$32.21 B
52w High$495.55
52w Low$197.81
Dividend Yield—
Frequency—
P/E43.37
Volume1.63M
Shares Out.133.81M

COMPANY

LEADERSHIP

Yvonne L. Greenstreet
CHIEF EXECUTIVE
Yvonne L. Greenstreet

COMPENSATION 2026

Salary$1,404,200
Stock Awards$5,512,500
Incentive Plan Pay$3,562,500
All Other Comp.$25,020
Total$14,867,600

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 1, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2,500

PRICE TARGET

Target High$455.00
Target Low$230.00
Target Median$334.00
Target Consensus$344.83

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$1.43B
OCT
29
THU

PRICE

$240.69 ▲ UP 1.51% (+$3.59)
$234$237$240$2439:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM240.69

About Alnylam Pharmaceuticals, Inc.

https://www.alnylam.com ↗

Alnylam Pharmaceuticals develops RNAi-based therapeutics for genetic, cardio-metabolic, hepatic, CNS, and ocular diseases, with marketed products like ONPATTRO, GIVLAARI, and OXLUMO, and collaborates with major pharma companies worldwide.

INDUSTRY

Biotechnology

A PRODUCT ALNYLAM PHARMACEUTICALS, INC. IS KNOWN FOR

AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran)

AMVUTTRA is an FDA-approved RNAi therapy for treating ATTR-CM and hATTR-PN in adults, now the only treatment approved for both primary manifestations of transthyretin-mediated amyloidosis, marking Alnylam's flagship product.

COMPETITORS

COMPETITOR
ARWR COMPARE
AZN COMPARE
BBIO COMPARE
IONS COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q4-2025Q1-2026Q2-2026
Product$672.21M — $1.04B ▲$1.17B ▲
GIVLAARI$80.85M $160.67M ▲$74.39M ▼$89.76M ▲
ONPATTRO$52.54M $70.76M ▲$20.48M ▼$18.46M ▼

Revenue by Geography

MapREGIONQ2-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$361.35M $1.17B ▲$702.55M ▼$809.08M ▲
Europe$92.87M $232.94M ▲$113.31M ▼$119.01M ▲
NonUS Or Europe$37.74M $107.04M ▲$74.06M ▼$83.67M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
773
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.04% · 4.3M
QQQ
0.14% · 2.9M
IBB
2.24% · 990.2K
TCAF
2.12% · 753.2K
CGGR
0.69% · 740.9K
XBI
0.72% · 363.7K
SCHG
0.12% · 323.7K
FBT
2.47% · 303.0K
JEPQ
0.17% · 292.6K
FMDE
0.39% · 137.2K
GSLC
0.16% · 106.4K
QQQI
0.14% · 85.7K
TQQQ
0.05% · 80.7K
XDWH.DE
0.36% · 62.5K
BBH
2.53% · 51.4K
QYLD
0.14% · 50.5K
FLQM
0.73% · 48.5K
QQQE
0.76% · 47.9K
XZ
XZME.F
0.11% · 45.1K
AMEL.DE
0.65% · 40.6K
DUHP
0.07% · 39.2K
NUMG
2.23% · 37.8K
NDQ.AX
0.14% · 37.6K
QGRW
0.25% · 31.1K
PB
PBPH
0.68% · 29.9K
HMWD.L
0.04% · 29.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.03%
HOLDERS
1,212
TOP 12 OF 1,212 · RANKED BY POSITION SIZE
Fmr LLC
16.8M sh · $7.65B
Capital World Investors
16.4M sh · $7.49B
Vanguard Group Inc
13.6M sh · $6.19B
Blackrock, Inc.
10.9M sh · $3.28B
Capital Research Global Investors
9.8M sh · $2.94B
Blackrock Inc.
9.5M sh · $2.32B
Jpmorgan Chase & Co
6.3M sh · $2B
T. Rowe Price Investment Management, Inc.
5.6M sh · $1.7B
Groupama Asset Managment
4.0M sh · $18.61M
Invesco Ltd.
3.8M sh · $1.13B
State Street Corp
3.6M sh · $1.07B
Baillie Gifford & Co
2.8M sh · $1.27B

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Jefferson Shreve
Jefferson Shreve
Sale
2025-05-12
 Josh Gottheimer
Josh Gottheimer
Sale (Full)
2024-01-29
 Daniel Goldman
Daniel Goldman
Purchase
2023-03-06
 Ro Khanna
Ro Khanna
Sale
2023-02-10

INSIDER TRADES

★
DIRECTOR
PYOTT DAVID E I
Sale · 17 shares
2026-06-01
★
DIRECTOR
Cravatt Benjamin
Purchase · 4.4K shares
2026-06-01
★
DIRECTOR:
Cravatt Benjamin
— · —
2026-06-01
★
DIRECTOR
PYOTT DAVID E I
Sale · 1.2K shares
2026-06-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 11
OUTPERFORM 4
OVERWEIGHT 3
EQUAL WEIGHT 2
STRONG BUY 1
HOLD 1
MARKET PERFORM 1
23 GRADES IN THE LAST 12 MONTHS
BMO Capital OUTPERFORM Wells Fargo EQUAL WEIGHT Truist Securities BUY HC Wainwright & Co. BUY Raymond James STRONG BUY Barclays OVERWEIGHT Citigroup BUY JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
REGN$797.70COMPARE
CI$277.21COMPARE
ARGX$1024.59COMPARE
COR$323.67COMPARE
CAH$235.49COMPARE
EW$90.92COMPARE
BDX$187.86COMPARE
VEEV$290.28COMPARE